Erber, Ramona <br/><br/>
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.  [electronic resource] 

 -  Breast cancer research and treatment  Apr 2015 
 - 279-88 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-015-3310-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Neoplasm--genetics<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>DNA Topoisomerases, Type II--genetics<br/>DNA-Binding Proteins--genetics<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Multivariate Analysis<br/>Prognosis<br/>Proportional Hazards Models<br/>Receptor, ErbB-2--genetics<br/>Risk<br/>Taxoids--administration & dosage<br/>Tissue Inhibitor of Metalloproteinase-1--metabolism<br/>Treatment Outcome